U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H14N2
Molecular Weight 198.2637
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TACRINE

SMILES

NC1=C2C=CC=CC2=NC3=C1CCCC3

InChI

InChIKey=YLJREFDVOIBQDA-UHFFFAOYSA-N
InChI=1S/C13H14N2/c14-13-9-5-1-3-7-11(9)15-12-8-4-2-6-10(12)13/h1,3,5,7H,2,4,6,8H2,(H2,14,15)

HIDE SMILES / InChI
Molecular Formula C13H14N2
Molecular Weight 198.2637
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/cognex.html

Tacrine is a parasympathomimetic- a reversible cholinesterase inhibitor that is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Tacrine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine at cholinergic synapses through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, tacrine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that tacrine alters the course of the underlying dementing process. The mechanism of tacrine is not fully known, but it is suggested that the drug is an anticholinesterase agent which reversibly binds with and inactivates cholinesterases. This inhibits the hydrolysis of acetylcholine released from functioning cholinergic neurons, thus leading to an accumulation of acetylcholine at cholinergic synapses. The result is a prolonged effect of acetylcholine. is used for the palliative treatment of mild to moderate dementia of the Alzheimer's type. Tacrine was marketed under the trade name Cognex. Because of its liver toxicity and attendant requirement for monitoring liver function, tacrine prescriptions dropped after other acetylcholinesterase inhibitors were introduced, and its use has been largely discontinued.

CNS Activity

Originator

Warner-Lambert
27
Curator's Comment: Originally developed by Warner-Lambert Co.

Approval Year

1993
138
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 500.0 nM [IC50]
Inhibitor
8504
 23.0 nM [IC50]
Inhibitor
8504
 0.46 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Cognex

Approved Use

Cognex® (tacrine hydrochloride capsules) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.

Launch Date

1993
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
15.8 ng/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7836549
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TACRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
91.8 ng × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7836549
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TACRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.8 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/7836549
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TACRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
Health Status: unhealthy
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Disc. AE: Nausea, Vomiting...
AEs leading to
discontinuation/dose reduction:
Nausea (21 patient)
Vomiting (21 patient)
Anorexia (21 patient)
Dyspepsia (21 patient)
Diarrhea (21 patient)
Abdominal pain (21 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Disc. AE: Transaminases increased, Atrial fibrillation...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Atrial fibrillation (1 patient)
Dyspnea (1 patient)
Chest pain (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Disc. AE: Transaminases increased, Nausea...
AEs leading to
discontinuation/dose reduction:
Transaminases increased (1 patient)
Nausea (1 patient)
Vomiting (1 patient)
Pallor (1 patient)
Vasodilatation (1 patient)
Sweating increased (1 patient)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
AEs

AEs

AESignificanceDosePopulation
Abdominal pain 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
Health Status: unhealthy
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Anorexia 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
Health Status: unhealthy
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Diarrhea 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
Health Status: unhealthy
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Dyspepsia 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
Health Status: unhealthy
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Nausea 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
Health Status: unhealthy
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Vomiting 21 patient
Disc. AE
160 mg 1 times / day multiple, oral
Highest studied dose
Dose: 160 mg, 1 times / day
Route: oral
Route: multiple
Dose: 160 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
unhealthy, 71.2 years (range: 52-88 years)
Health Status: unhealthy
Age Group: 71.2 years (range: 52-88 years)
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/9236571
https://pubmed.ncbi.nlm.nih.gov/8139083
Atrial fibrillation 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Chest pain 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Dyspnea 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Transaminases increased 1 patient
Disc. AE
40 mg 1 times / day multiple, oral
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Nausea 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Pallor 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Sweating increased 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Transaminases increased 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Vasodilatation 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Vomiting 1 patient
Disc. AE
80 mg 1 times / day multiple, oral
Recommended
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020070ap.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1197

OCT1
393

OCT3
92

OCTN2
59

P-gp
2052
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
P-gp
2052
 inconclusive
CYP1A2
1197
 yes
OCT1
393
 yes
OCT3
92
 yes
OCTN2
59
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:45980
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:45980
ChemicalBook
CB7699634
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB7699634
eMolecules
872890
https://www.emolecules.com/cgi-bin/more?vid=872890
MolPort
MolPort-000-881-472
https://www.molport.com/shop/molecule-link/MolPort-000-881-472
ZINC
ZINC000019014866
http://zinc15.docking.org/substances/ZINC000019014866
PubMed

PubMed

TitleDatePubMed
N-palmitoyl serotonin alleviates scopolamine-induced memory impairment via regulation of cholinergic and antioxidant systems, and expression of BDNF and p-CREB in mice.
2015-12-05
A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.
2014-01
Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model.
2013-12
Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors.
2013-03-25
Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation.
2011-08
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011-07-14
A second-generation device for automated training and quantitative behavior analyses of molecularly-tractable model organisms.
2010-12-17
Dual-acting drugs: an in vitro study of nonimidazole histamine H3 receptor antagonists combining anticholinesterase activity.
2010-07-05
Synthesis and AChE inhibitory activity of new chiral tetrahydroacridine analogues from terpenic cyclanones.
2010-02
A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.
2010-01-18
Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.
2010-01-12
Contribution of the d-Serine-Dependent Pathway to the Cellular Mechanisms Underlying Cognitive Aging.
2010
Tacrine-NO donor and tacrine-ferulic acid hybrid molecules as new anti-Alzheimer agents: hepatotoxicity and influence on the cytochrome P450 system in comparison to tacrine.
2010
Rapid determination of tacrine and other drug metabolites in microsomal incubate by newly developed targeting algorithm on UHPLC/TOFMS.
2009-12-15
Coupling an HCN2-expressing cell to a myocyte creates a two-cell pacing unit.
2009-11-01
Long-lasting decreases in cocaine-reinforced behavior following treatment with the cholinesterase inhibitor tacrine in rats selectively bred for drug self-administration.
2009-11
Cholinergic influence on memory stages: A study on scopolamine amnesic mice.
2009-08
An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells.
2009-06-01
Determination of basic azaarenes in aviation kerosene by solid-phase extraction and HPLC-fluorescence detection.
2009-06
Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) utricle.
2009-06
Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease.
2009-02-06
Effects of zonisamide on c-Fos expression under conditions of tacrine-induced tremulous jaw movements in rats: a potential mechanism underlying its anti-parkinsonian tremor effect.
2009-01
Comparison studies of tacrine and bis7-tacrine on the suppression of scopolamine-induced behavioral changes and inhibition of acetylcholinesterase in mice.
2009
The 5-choice continuous performance test: evidence for a translational test of vigilance for mice.
2009
NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity.
2008-12-25
Comparative effects of cationic triarylmethane, phenoxazine and phenothiazine dyes on horse serum butyrylcholinesterase.
2008-10-15
New performance of biosensor technology for Alzheimer's disease drugs: in vitro comparison of tacrine and 7-methoxytacrine.
2008-10
The investigation of structure-activity relationships of tacrine analogues: electronic-topological method.
2008-08-06
1-Phenyl-6,7,8,9-hexa-hydro-1H,5H-cyclo-hepta-[1',2':2,3]pyrido[6,5-c]pyrazol-4-amine: a new tacrine analogue.
2008-05-10
Current therapeutic options for Alzheimer's disease.
2007-12
Allosteric modulation of muscarinic acetylcholine receptors.
2007-09
Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.
2007-06
Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease.
2007
Progress update: Pharmacological treatment of Alzheimer's disease.
2007
The evaluation of cognitive function in the dementias: methodological and regulatory considerations.
2003-03
Sleep-wake mechanisms and drug discovery: sleep EEG as a tool for the development of CNS-acting drugs.
2002-12
Therapeutic approaches to age-associated neurocognitive disorders.
2001-09
Adverse interaction of tacrine and haloperidol.
1996-11
Delirium caused by tacrine and ibuprofen interaction.
1996-06
Convulsive effects of tacrine.
1996-05-11
Systemic administration of lithium chloride and tacrine but not kainic acid augments citrulline content of rat brain.
1995-12-27
Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol.
1995-08
Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats.
1993-11-30
Tacrine inhibits ventricular fibrillation induced by ischaemia and reperfusion and widens QT interval in rat.
1993-03
A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice.
1990-11
Correlation of brain levels of 9-amino-1,2,3,4-tetrahydroacridine (THA) with neurochemical and behavioral changes.
1989-11-28
Amino acridines action on Friend's retrovirus in relation to their molecular ionization.
1989
Suxamethonium apnoea masked by tetrahydroaminacrine.
1978-07-01
Ketamine-induced postanesthetic delirium attenuated by tetrahydroaminoacridine.
1974-07
An appraisal of tacrine-extended suxamethonium.
1970-02
Patents

Patents

05013741
3
JP2003512428A
9
JP2004315496A
25
JP2007508336A
3
JP4722295B2
105
JPH0366670A
3
JPH0820577A
3

Sample Use Guides

In Vivo Use Guide
Oral Initially, 10 mg 4 times daily for at least 4 weeks. If well tolerated and increased serum ALT concentrations have not occurred, increase dosage to 20 mg 4 times daily; if tolerated, increase dosage in 40-mg daily increments (divided into 4 doses daily) at 4-week intervals up to a maximum of 160 mg daily (40 mg 4 times daily).
Route of Administration: Oral
In Vitro Use Guide
Tacrine (0.01-10 uM) inhibited both human and rat HNMT activity in a concentration-dependent manner, but was less potent on both human embryonic kidney and recombinant human brain HNMT than on rat kidney HNMT (IC50 values were 0.46 and 0.70 uM vs. 0.29 uM, respectively).
Substance Class Chemical
Created
by admin
on Wed Apr 02 08:21:01 GMT 2025
Edited
by admin
on Wed Apr 02 08:21:01 GMT 2025
Record UNII
4VX7YNB537
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TACRINAL
Preferred Name English
TACRINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
Tacrine [WHO-DD]
Common Name English
TACRINE [VANDF]
Common Name English
tacrine [INN]
Common Name English
TACRINE [MI]
Common Name English
9-AMINO-1,2,3,4-TETRAHYDROACRIDINE
Systematic Name English
Classification Tree Code System Code
WHO-ATC N06DA01
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
NDF-RT N0000175723
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
WHO-VATC QN06DA01
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
NDF-RT N0000000177
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
NCI_THESAURUS C47792
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
LIVERTOX NBK547868
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
Code System Code Type Description
EPA CompTox
DTXSID1037272
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
CHEBI
45980
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
ChEMBL
CHEMBL95
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
PUBCHEM
1935
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
NCI_THESAURUS
C61961
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
MERCK INDEX
m10424
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY Merck Index
IUPHAR
6687
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
RXCUI
10318
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY RxNorm
SMS_ID
100000082994
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
ECHA (EC/EINECS)
206-291-2
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
EVMPD
SUB10796MIG
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
FDA UNII
4VX7YNB537
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
DRUG CENTRAL
2551
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
INN
800
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
CAS
321-64-2
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
MESH
D013619
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
WIKIPEDIA
TACRINE
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
DRUG BANK
DB00382
Created by admin on Wed Apr 02 08:21:01 GMT 2025 , Edited by admin on Wed Apr 02 08:21:01 GMT 2025
PRIMARY
Related Record Type Details
CYTOCHROME P450 1A1
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Histamine N-methyltransferase
OFF-TARGET->INHIBITOR
HNMT inhibitors may increase histamine levels in peripheral tissues and exacerbate histamine-related diseases, such as allergic rhinitis, urticaria, and peptic ulcer disease. However, the effect of HNMT inhibitors on brain function is not yet fully understood. Some studies suggest that an increase in brain histamine levels by novel HNMT inhibitors could contribute to the improvement of brain disorders.
IC50
ACETYLCHOLINESTERASE HUMAN
TARGET -> INHIBITOR
IC50
ACETYLCHOLINESTERASE HUMAN
TARGET -> INHIBITOR
IC50
ALDEHYDE OXIDASE
METABOLIC ENZYME -> INHIBITOR
IC50
Structure of TACRINE HYDROCHLORIDE MONOHYDRATE
SALT/SOLVATE -> PARENT
Structure of TACRINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
Structure of 3-HYDROXYTACRINE
METABOLITE -> PARENT
URINE
Structure of VELNACRINE
METABOLITE ACTIVE -> PARENT
URINE
Structure of 4-HYDROXYTACRINE
METABOLITE -> PARENT
URINE
Structure of 9-AMINO-1,2,3,4-TETRAHYDRO-1,3-ACRIDINEDIOL
METABOLITE -> PARENT
URINE
Structure of 2-HYDROXYTACRINE
METABOLITE -> PARENT
URINE
Related Record Type Details
Structure of TACRINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966